english.prescrire.org > Prescrire International > N°126 - April 2012

n°126

April 2012

Issue Contents
New Products

Free  Screening: tell the truth

p.88
Informing patients does not necessarily imply lower participation

Boceprevir (New Drug)

p.89-92
In triple-drug combination: virological advantage in chronic hepatitis C

Telaprevir (New Drug)

p.93-96
After boceprevir, if necessary

INN common stem: -previr

p.96

Adverse Effects


Bupropion: congenital heart defects (continued)

p.97
Yet another reason to avoid bupropion

Opioids and hypogonadism

p.98-99
Patients should be informed

Publicly accessible pharmacovigilance databases

p.99
Already available in 4 countries

Fingolimod: cardiovascular deaths

p.99
Pharmacovigilance confirms adverse signals noticed prior to market release

Reviews


HIV exposure through contact with body fluids

p.100-105
Urgently assess the risk of infection and treat for 28 days if necessary

Assessing the risk of HIV infection after an isolated exposure incident

p.102-103

The French procedure for emergency management of HIV exposure

p.105

Outlook


Free  New drugs and indications in 2011. France is better focused on patients' interests after the Mediator° scandal, but stagnation elsewhere

p.106-110

Free  Drugs best avoided yet still on the market in early 2012

p.108

Free  French drug policy: a few timid steps taken in 2011

p.109

Free  In the wake of the Mediator° scandal: some progress in France, but apathy at the European level

p.110

Free  Fingolimod (Gilenya°): EMA's lack of transparency spells danger for patients

p.112

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe